1832 Asset Management
ACHN

1832 Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

1832 Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,500
Closed -$7K – 765
2017
Q4 		$7K Buy
+2,500
New +$9.08K ﹤0.01% 625

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

1832 Asset Management's ACHN Position: Q1 2018 in Review

1832 Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 2,500 shares — an estimated $7K sold.

1832 Asset Management first reported a position in ACHN in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • 1832 Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • 1832 Asset Management sold 2,500 Achillion Pharmaceuticals shares in Q1 2018, an estimated $7K.
  • 1832 Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • 1832 Asset Management's Achillion Pharmaceuticals position peaked at $7K in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on 1832 Asset Management's 13F filing for Q1 2018, filed 15 May 2018.